Search

Your search keyword '"Zieroth, Shelley"' showing total 548 results
Start Over Author "Zieroth, Shelley"
548 results on '"Zieroth, Shelley"'

3. An Internet-Based Counseling Intervention With Email Reminders that Promotes Self-Care in Adults With Chronic Heart Failure: Randomized Controlled Trial Protocol

Author

Nolan, Robert P, Payne, Ada YM, Ross, Heather, White, Michel, D'Antono, Bianca, Chan, Sammy, Barr, Susan I, Gwadry-Sridhar, Femida, Nigam, Anil, Perreault, Sylvie, Farkouh, Michael, McDonald, Michael, Goodman, Jack, Thomas, Scott, Zieroth, Shelley, Isaac, Debra, Oh, Paul, Rajda, Miroslaw, Chen, Maggie, Eysenbach, Gunther, Liu, Sam, and Zbib, Ahmad

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundChronic heart failure (CHF) is a public health priority. Its age-standardized prevalence has increased over the past decade. A major challenge for the management of CHF is to promote long-term adherence to self-care behaviors without overtaxing available health care resources. Counseling by multidisciplinary health care teams helps to improve adherence to self-care behaviors and to reduce the rate of death and hospitalization. In the absence of intervention, adherence to self-care is below recommended standards. ObjectiveThis trial aims to establish and evaluate a Canadian e-platform that will provide a core, standardized protocol of behavioral counseling and education to facilitate long-term adherence to self-care among patients with CHF. MethodsCanadian e-Platform to Promote Behavioral Self-Management in Chronic Heart Failure (CHF-CePPORT) is a multi-site, double blind, randomized controlled trial with a 2 parallel-group (e-Counseling + Usual Care vs e-Info Control + Usual Care) by 3 assessments (baseline, 4-, and 12-month) design. We will identify subjects with New York Heart Association Class II or III systolic heart failure from collaborating CHF clinics and then recruit them (n=278) by phone. Subjects will be randomized in blocks within each site (Toronto, Montreal, and Vancouver). The primary outcome will be improved quality of life, defined as an increased number of subjects with an improvement of ≥5 points on the summary score of the Kansas City Cardiomyopathy Questionnaire. We will also assess the following secondary outcomes: (1) diet habits, depression, anxiety, smoking history, stress level, and readiness for change using self-report questionnaires, (2) physical activity level, current smoking status, and vagal-heart rate modulation by physiological tests, and (3) exercise capacity, prognostic indicators of cardiovascular functioning, and medication adherence through medical chart review. The primary outcome will be analyzed using generalized estimation equations with repeated measures on an intention-to-treat basis. Secondary outcomes will be analyzed using repeated-measures linear mixed models with a random effects intercept. All significant main effects or interactions in the statistical models will be followed up with post hoc contrasts using a Bonferroni correction with a 2-sided statistical significance criterion of P

Published
2014
Full Text
View/download PDF

4. Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017.

Author

Matetic, Andrija, Ky, Bonnie, Yang, Eric H, Myint, Phyo K, Rashid, Muhammad, Zieroth, Shelley, Paul, Timir K, Elbadawi, Ayman, and Mamas, Mamas A

Abstract

Pericardiocentesis is undertaken in patients with cancer for diagnostic and therapeutic purposes. However, there are limited data on the frequency, characteristics and mortality of patients with different cancers undergoing pericardiocentesis.All hospitalisations of adult cancer patients (≥18 years) in the US National Inpatient Sample between January 2004 and December 2017 were included. The cohort was stratified by discharge code of pericardiocentesis and cancer, using the International Classification of Diseases. The prevalence of pericardiocentesis, patient characteristics, cancer types and in-hospital all-cause mortality were analysed between cancer patients undergoing pericardiocentesis versus not.A total of 19,773,597 weighted cancer discharges were analysed, out of which 18,847 (0.1%) underwent pericardiocentesis. The most common cancer types amongst the patients receiving pericardiocentesis were lung (51.3%), haematological (15.9%), breast (5.4%), mediastinum/heart (3.2%), gastroesophageal (2.2%) and female genital cancer (1.8%), whilst 'other' cancer types were present in 20.2% patients. Patients undergoing pericardiocentesis had significantly higher mortality (15.6% vs. 4.2%, p

Published
2022

5. Diagnostic and therapeutic practice for Heart Failure with preserved ejection fraction around the world: An international survey

Author

Saldarriaga, Clara, de Gracia, Sydney Stephanie Goldfeder, Mejia, Maria Isabel Palacio, Shchendrygina, Anastasia, Kida, Keisuke, Fauvel, Charles, Zaleska-Kociecka, Marta, Mapelli, Massimo, Einarsson, Hafsteinn, Guidetti, Federica, Robledo, Gina Gonzalez, Milinkovic, Ivan, Esperon, Guillermina, Tejero, Alberto, Meznar, Anja Zupan, Rustamova, Yasmin, Vishram-Nielsen, Julie, Mohty, Dania, Zieroth, Shelley, Barasa, Anders, Ingimarsdóttir, Inga Jóna, Tun, Han Naung, Tham, Novi, Rakotonoel, Rolland, Rosano, Giuseppe M.C., Ruschitzka, Frank, and Mewton, Nathan

Published
2024
Full Text
View/download PDF

6. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

Author

Udell, Jacob A., Petrie, Mark C., Jones, W. Schuyler, Anker, Stefan D., Harrington, Josephine, Mattheus, Michaela, Seide, Svenja, Amir, Offer, Bahit, M. Cecilia, Bauersachs, Johann, Bayes-Genis, Antoni, Chen, Yundai, Chopra, Vijay K., Figtree, Gemma, Ge, Junbo, Goodman, Shaun G., Gotcheva, Nina, Goto, Shinya, Gasior, Tomasz, Jamal, Waheed, Januzzi, James L., Jeong, Myung Ho, Lopatin, Yuri, Lopes, Renato D., Merkely, Béla, Martinez-Traba, Monica, Parikh, Puja B., Parkhomenko, Alexander, Ponikowski, Piotr, Rossello, Xavier, Schou, Morten, Simic, Dragan, Steg, Philippe Gabriel, Szachniewicz, Joanna, van der Meer, Peter, Vinereanu, Dragos, Zieroth, Shelley, Brueckmann, Martina, Sumin, Mikhail, Bhatt, Deepak L., Hernandez, Adrian F., and Butler, Javed

Published
2024
Full Text
View/download PDF

9. Prevention of heart failure

Author

Piepoli, Massimo Francesco, additional, Matrone, Maria Benedetta, additional, Dendale, Paul, additional, and Zieroth, Shelley, additional

Published
2023
Full Text
View/download PDF

13. The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference

Author

DRAZNER, MARK H., AMBARDEKAR, AMRUT V., BERLACHER, KATHRYN, BLUMER, VANESSA, CHATUR, SAFIA, CHENG, RICHARD, CHENG, RICHARD K., GRANDIN, E. WILSON, GORODESKI, EIRAN Z., KATARIA, RACHNA, KATZ, JASON N., KITTLESON, MICHELLE M., KRISHNAMOORTHY, ARUN, LALA, ANURADHA, LENNEMAN, ANDREW J., LOHR, NICOLE L., MARGULIES, KENNETH B., MENTZ, ROBERT J., REZA, NOSHEEN, WILCOX, JANE, YOUMANS, QUENTIN R., ZIEROTH, SHELLEY, and TEERLINK, JOHN R.

Published
2024
Full Text
View/download PDF

18. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

19. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

22. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations

Author

Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Jr, Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed

Published
2023
Full Text
View/download PDF

28. The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network

Author

Cowie, Martin R., Mourilhe-Rocha, Ricardo, Chang, Hung-Yu, Volterrani, Maurizio, Ban, Ha Ngoc, Campos de Albuquerque, Denilson, Chung, Edward, Fonseca, Cândida, Lopatin, Yuri, Magaña Serrano, José Antonio, Mircheva, Lilyana, Moncada-Paz, Gustavo Adolfo, Pagava, Zurab, Reyes, Eugenio B., Saldarriaga, Clara, Schwartzmann, Pedro, Sim Kheng Leng, David, Trivi, Marcelo, Yotov, Yoto Trifonov, and Zieroth, Shelley

Published
2022
Full Text
View/download PDF

29. Regulatory T Cell Biomarkers Identify Patients at Risk of Developing Acute Cellular Rejection in the First Year Following Heart Transplantation

Author

Kim, Ji-Young V., Assadian, Sara, Hollander, Zsuzsanna, Burns, Paloma, Shannon, Casey P., Lam, Karen, Toma, Mustafa, Ignaszewski, Andrew, Davies, Ross A., Delgado, Diego, Haddad, Haissam, Isaac, Debra, Kim, Daniel, Mui, Alice, Rajda, Miroslaw, West, Lori, White, Michel, Zieroth, Shelley, Keown, Paul A., McMaster, W. Robert, Ng, Raymond T., McManus, Bruce M., Levings, Megan K., and Tebbutt, Scott J.

Published
2023
Full Text
View/download PDF

30. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

Author

Mancini, G.B. John, O’Meara, Eileen, Zieroth, Shelley, Bernier, Mathieu, Cheng, Alice Y.Y., Cherney, David Z.I., Connelly, Kim A., Ezekowitz, Justin, Goldenberg, Ronald M., Leiter, Lawrence A., Nesrallah, Gihad, Paty, Breay W., Piché, Marie-Eve, Senior, Peter, Sharma, Abhinav, Verma, Subodh, Woo, Vincent, Darras, Pol, Gabor, Jonathan Y., Grégoire, Jean, Lonn, Eva, Stone, James A., Yale, Jean-François, Yeung, Colin, and Zimmerman, Deborah

Published
2022
Full Text
View/download PDF

32. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Author

Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, and Ponikowski, Piotr

Published
2022
Full Text
View/download PDF

34. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial

Author

Ezekowitz, Justin, Colin-Ramirez, Eloisa, Ross, Heather, Escobedo, Jorge, Macdonald, Peter, Troughton, Richard, Saldarriaga, Clara, Alemayehu, Wendimagegn, McAlister, Finlay, Arcand, JoAnne, Atherton, John, Doughty, Robert, Gupta, Milan, Howlett, Jonathan, Jaffer, Shahin, Lavoie, Andrea, Lund, Mayanna, Marwick, Thomas, McKelvie, Robert, Moe, Gordon, Pandey, A. Shekhar, Porepa, Liane, Rajda, Miroslaw, Rheault, Haunnah, Singh, Jitendra, Toma, Mustafa, Virani, Sean, Zieroth, Shelley, Ezekowitz, Justin A, McAlister, Finlay A, and Pandey, A Shekhar

Published
2022
Full Text
View/download PDF

35. Applicability of heart failure clinical practice guidelines in low‐ and middle‐income countries.

Author

Zieroth, Shelley, Giraldo, Clara Inés Saldarriaga, Pinto, Fausto, Anker, Stefan D., Abraham, William T., Atherton, John J., Butler, Javed, Chopra, Vijay, Coats, Andrew J.S., Dean, Veronica, Filippatos, Gerasimos, Zamorano, Jose Luis, Zhang, Yuhui, Weiskopf, Richard B., and Colardelle, Yann

Subjects
*HEART failure, *MEDICAL databases, *TRANSLATIONAL research, *PROFESSIONAL associations, *INTERNET surveys
Abstract

Aims Methods and results Conclusion Clinical practice guidelines are commonly written by professional societies in high‐income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability in low‐ and middle‐income countries (LMIC).An online survey of physicians in the database of the Translational Medicine Academy who treat HF patients was offered by email from 5 October to 27 November 2023, inquiring of participants' demographic information, experience, and views of HF guidelines as related to their practice. Of 2622 participating clinicians, 1592 partially completed, and an additional 1030 fully completed the survey. Participants were from 138 countries; 668 practiced in HIC, and 1954 in LMIC. Those from LMIC regarded HF guidelines to be less applicable in their country than did those from HIC (p = 0.0002). Of all those responding, 75.3% indicated that it was somewhat or mostly true that the HF guidelines were mostly applicable to HIC. Those from LMIC, but not HIC indicated that the greatest implementation obstacle was that the guidelines were for HIC (51.3% vs. 43.1%; p = 0.0387). A significantly higher proportion of respondents from LMIC indicated that resources for caring for their patients were somewhat or mostly limiting in most cases, than did those in HIC (41.6% vs. 32.5%, p = 0.0068).This survey examined the widely‐held thought that HF guidelines are broadly applicable to all regions of the world, concluding that such a perception is incorrect. Clinicians from LMIC view the absence of consideration of local resource limitations as the greatest obstacle for guideline implementation. The results regarding HF guidelines likely also have implications for other guidelines and resultant patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

Author

Solomon, Scott D., primary, Ostrominski, John W., additional, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Pitt, Bertram, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Voors, Adriaan A., additional, Zannad, Faiez, additional, Abidin, Imran Zainal, additional, Alcocer‐Gamba, Marco Antonio, additional, Atherton, John J., additional, Bauersachs, Johann, additional, Ma, Chang‐Sheng, additional, Chiang, Chern‐En, additional, Chioncel, Ovidiu, additional, Chopra, Vijay, additional, Comin‐Colet, Josep, additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Gajos, Grzegorz, additional, Goland, Sorel, additional, Goncalvesová, Eva, additional, Kang, Seok‐Min, additional, Katova, Tzvetana, additional, Kosiborod, Mikhail N., additional, Latkovskis, Gustavs, additional, Lee, Alex Pui‐Wai, additional, Linssen, Gerard C.M., additional, Llamas‐Esperón, Guillermo, additional, Mareev, Vyacheslav, additional, Martinez, Felipe A., additional, Melenovský, Vojtěch, additional, Merkely, Béla, additional, Nodari, Savina, additional, Petrie, Mark C., additional, Saldarriaga, Clara Inés, additional, Saraiva, Jose Francisco Kerr, additional, Sato, Naoki, additional, Schou, Morten, additional, Sharma, Kavita, additional, Troughton, Richard, additional, Udell, Jacob A., additional, Ukkonen, Heikki, additional, Vardeny, Orly, additional, Verma, Subodh, additional, von Lewinski, Dirk, additional, Voronkov, Leonid G., additional, Yilmaz, Mehmet Birhan, additional, Zieroth, Shelley, additional, Lay‐Flurrie, James, additional, van Gameren, Ilse, additional, Amarante, Flaviana, additional, Viswanathan, Prabhakar, additional, and McMurray, John J.V., additional

Published
2024
Full Text
View/download PDF

38. MACE in COPD: addressing cardiopulmonary risk

Author

Hurst, John R, primary, Gale, Chris P, additional, Hurst, John R., additional, Bhutani, Mohit, additional, Bourbeau, Jean, additional, Han, MeiLan, additional, Hawkins, Nathaniel M., additional, Lam, Carolyn S.P., additional, Marciniuk, Darcy D., additional, Price, David, additional, Stolz, Daiana, additional, Zieroth, Shelley, additional, and Gale, Chris P., additional

Published
2024
Full Text
View/download PDF

39. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

Author

Wang, Xiaowen, Vaduganathan, Muthiah, Claggett, Brian L., Hegde, Sheila M., Pabon, Maria, Kulac, Ian J., Vardeny, Orly, O’Meara, Eileen, Zieroth, Shelley, Katova, Tzvetana, McGrath, Martina M., Pouleur, Anne-Catherine, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., Kosiborod, Mikhail N., de Boer, Rudolf A., Kober, Lars, Sabatine, Marc S., Martinez, Felipe A., Ponikowski, Piotr, Shah, Sanjiv J., Hernandez, Adrian F., Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

40. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Author

Bozkurt, Biykem, Coats, Andrew JS, Tsutsui, Hiroyuki, Abdelhamid, Magdy, Adamopoulos, Stamatis, Albert, Nancy, Anker, Stefan D., Atherton, John, Böhm, Michael, Butler, Javed, Drazner, Mark H., Felker, G. Michael, Filippatos, Gerasimos, Fonarow, Gregg C., Fiuzat, Mona, Gomez-Mesa, Juan–Esteban, Heidenreich, Paul, Imamura, Teruhiko, Januzzi, James, Jankowska, Ewa A., Khazanie, Prateeti, Kinugawa, Koichiro, Lam, Carolyn S.P., Matsue, Yuya, Metra, Marco, Ohtani, Tomohito, Francesco Piepoli, Massimo, Ponikowski, Piotr, Rosano, Giuseppe M.C., Sakata, Yasushi, SeferoviĆ, Petar, Starling, Randall C., Teerlink, John R., Vardeny, Orly, Yamamoto, Kazuhiro, Yancy, Clyde, Zhang, Jian, and Zieroth, Shelley

Published
2021
Full Text
View/download PDF

41. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

Author

McDonald, Michael, Virani, Sean, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge, Mielniczuk, Lisa, Moe, Gordon W., O’Meara, Eileen, Swiggum, Elizabeth, Toma, Mustafa, Zieroth, Shelley, Anderson, Kim, Bray, Sharon A., Clarke, Brian, Cohen-Solal, Alain, D’Astous, Michel, Davis, Margot, De, Sabe, Grant, Andrew D.M., Grzeslo, Adam, Heshka, Jodi, Keen, Sabina, Kouz, Simon, Lee, Douglas, Masoudi, Frederick A., McKelvie, Robert, Parent, Marie-Claude, Poon, Stephanie, Rajda, Miroslaw, Sharma, Abhinav, Siatecki, Kyla, Storm, Kate, Sussex, Bruce, Van Spall, Harriette, and Yip, Amelia Ming Ching

Published
2021
Full Text
View/download PDF

42. HEARTBiT: A Transcriptomic Signature for Excluding Acute Cellular Rejection in Adult Heart Allograft Patients

Author

Shannon, Casey P., Hollander, Zsuzsanna, Dai, Darlene L.Y., Chen, Virginia, Assadian, Sara, Lam, Karen K., McManus, Janet E., Zarzycki, Marek, Kim, YoungWoong, Kim, Ji-Young V., Balshaw, Robert, Gidlöf, Olof, Öhman, Jenny, Smith, J. Gustav, Toma, Mustafa, Ignaszewski, Andrew, Davies, Ross A., Delgado, Diego, Haddad, Haissam, Isaac, Debra, Kim, Daniel, Mui, Alice, Rajda, Miroslaw, West, Lori, White, Michel, Zieroth, Shelley, Tebbutt, Scott J., Keown, Paul A., McMaster, W. Robert, Ng, Raymond T., and McManus, Bruce M.

Published
2020
Full Text
View/download PDF

43. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis

Author

Fine, Nowell M., Davis, Margot K., Anderson, Kim, Delgado, Diego H., Giraldeau, Genevieve, Kitchlu, Abhijat, Massie, Rami, Narayan, Jane, Swiggum, Elizabeth, Venner, Christopher P., Ducharme, Anique, Galant, Natalie J., Hahn, Christopher, Howlett, Jonathan G., Mielniczuk, Lisa, Parent, Marie-Claude, Reece, Donna, Royal, Virginie, Toma, Mustafa, Virani, Sean A., and Zieroth, Shelley

Published
2020
Full Text
View/download PDF

44. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care

Author

Chih, Sharon, McDonald, Michael, Dipchand, Anne, Kim, Daniel, Ducharme, Anique, Kaan, Annemarie, Abbey, Susan, Toma, Mustafa, Anderson, Kim, Davey, Ryan, Mielniczuk, Lisa, Campbell, Patricia, Zieroth, Shelley, Bourgault, Christine, Badiwala, Mitesh, Clarke, Brian, Belanger, Eric, Carrier, Michel, Conway, Jennifer, Doucette, Karen, Giannetti, Nadia, Isaac, Debra, MacArthur, Rod, and Senechal, Mario

Published
2020
Full Text
View/download PDF

45. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

Author

O’Meara, Eileen, McDonald, Michael, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Grzeslo, Adam, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge, Mielniczuk, Lisa M., Moe, Gordon W., Swiggum, Elizabeth, Toma, Mustafa, Virani, Sean A., Zieroth, Shelley, De, Sabe, Matteau, Sylvain, Parent, Marie-Claude, Asgar, Anita W., Cohen, Gideon, Fine, Nowell, Davis, Margot, Verma, Subodh, Cherney, David, Abrams, Howard, Al-Hesayen, Abdul, Cohen-Solal, Alain, D’Astous, Michel, Delgado, Diego H., Desplantie, Olivier, Estrella-Holder, Estrellita, Green, Lee, Haddad, Haissam, Harkness, Karen, Hernandez, Adrian F., Kouz, Simon, LeBlanc, Marie-Hélène, Lee, Douglas, Masoudi, Frederick A., McKelvie, Robert S., Rajda, Miroslaw, Ross, Heather J., and Sussex, Bruce

Published
2020
Full Text
View/download PDF

48. Are the cardioprotective effects of the phytoestrogen resveratrol sex-dependent?

Author

Louis, Xavier Lieben, Raj, Pema, Chan, Laura, Zieroth, Shelley, Netticadan, Thomas, and Wigle, Jeffrey T.

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Postmenopausal women -- Analysis, Menopause -- Development and progression -- Risk factors -- Analysis, Mediation -- Analysis, Cardiovascular diseases -- Development and progression -- Risk factors -- Analysis, Estrogen -- Analysis, Apoptosis -- Analysis, Resveratrol -- Analysis, Atherosclerosis -- Development and progression -- Risk factors -- Analysis, Biological sciences
Abstract

Cardiovascular disease (CVD) is the number one cause of death in both men and women. Younger women have a lower risk for CVD, but their risk increases considerably after menopause when estrogen levels decrease. The cardiovascular protective properties of estrogen are mediated through decreasing vascular inflammation and progression of atherosclerosis, decreasing endothelial cell damage by preventing apoptosis and anti-hypertrophic mechanisms. Estrogen also regulates glucose and lipid levels, which are 2 important risk factors for CVD. Resveratrol (RES), a cardioprotective polyphenolic compound, is classified as a phytoestrogen due its capacity to bind to and modulate estrogen receptor signalling. Due to its estrogen-like property, we speculate that the cardioprotective effects of RES treatment could be sex-dependent. Based on earlier reports and more recent data from our lab presented here, we found that RES treatment may have more favourable cardiovascular outcomes in females than in males. This review will discuss estrogen- and phytoestrogen-mediated cardioprotection, with a specific focus on sexdependent effects reported in preclinical and clinical studies. Key words: resveratrol, phytoestrogen, estrogen, sex-dependent cardioprotection, polyphenol, cardiovascular disease. Les maladies cardiovasculaires (MCV) sont la principale cause de deces autant chez les hommes que chez les femmes. Les femmes jeunes sont exposees a un plus faible risque de MCV, mais leur risque augmente considerablement apres la menopause, quand les taux d'restrogenes decroissent. Les proprietes protectrices des restrogenes contre les MCV sont mediees par l'intermediaire d'une diminution de l'inflammation vasculaire et le ralentissement de la progression de l'atherosclerose, lesquelles entrainent une attenuation des lesions des cellules endotheliales par la prevention de l'apoptose et de modes d'action contre l'hypertrophie. Les restrogenes participent aussi a la regulation de la glycemie et des taux de lipides, lesquels sont d'importants facteurs de risque des MCV. Le resveratrol (RES), un compose polyphenol cardioprotecteur, est classe parmi les phytorestrogenes en raison de sa capacite de se lier aux recepteurs aux restrogenes et a en modifier la signalisation. En raison de ses proprietes ressemblant a celles des restrogenes, nous posons l'hypothese selon laquelle les effets cardioprotecteurs du traitement par le RES peuvent varier selon le sexe. A partir de rapports anterieurs et de donnees plus recentes issues de nos laboratoires que nous presentons ici, nous avons observe que le traitement par le RES pourrait permettre d'obtenir des resultats plus favorables chez les femmes que chez les hommes sur le plan cardiovasculaire. Dans cet article de synthese, nous discutons de la mediation de la cardioprotection par des restrogenes et des phytorestrogenes, en nous centrant plus particulierement sur les effets rapportes en fonction du sexe dans le cadre d'etudes precliniques et cliniques. [Traduit par la Redaction] Mots-cles : resveratrol, phytorestrogenes, restrogenes, variations de la cardioprotection selon le sexe, polyphenol, maladies cardiovasculaires., Introduction Globally, cardiovascular disease (CVD) is the number one cause of mortality (WHO 2017). In 2015, 422.7 million people worldwide were diagnosed with CVD and 17.7 million people died (31% [...]

Published
2019
Full Text
View/download PDF

50. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

Author

Anker, Stefan D., primary, Usman, Muhammad Shariq, additional, Anker, Markus S., additional, Butler, Javed, additional, Böhm, Michael, additional, Abraham, William T., additional, Adamo, Marianna, additional, Chopra, Vijay K., additional, Cicoira, Mariantonietta, additional, Cosentino, Francesco, additional, Filippatos, Gerasimos, additional, Jankowska, Ewa A., additional, Lund, Lars H., additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Gonzalez‐Juanatey, Jose R., additional, Rakisheva, Amina, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Teerlink, John R., additional, Tschöpe, Carsten, additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, Zhang, Jian, additional, Zhang, Yuhui, additional, Bauersachs, Johann, additional, Landmesser, Ulf, additional, Zieroth, Shelley, additional, Tsioufis, Konstantinos, additional, Bayes‐Genis, Antoni, additional, Chioncel, Ovidiu, additional, Andreotti, Felicita, additional, Agabiti‐Rosei, Enrico, additional, Merino, Jose L., additional, Metra, Marco, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results